secwatch.observer — SEC 8-K summary
======================================

Issuer:     Q/C TECHNOLOGIES, INC. (QCLS)
CIK:        0001321834
Form:       8-K
Filed at:   2023-10-19T23:59:59+00:00
Accession:  0001493152-23-037679
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MyMD Supera-CBD preclinical study shows rapid pain relief; Japanese patent granted
--------------------------------------------------------------------------------

- Supera-CBD reduced acute inflammatory heat pain within 60 minutes; relief lasted up to five hours; traditional CBD had no effect.
- Study at major academic center suggests Supera-CBD targets TRPV1 channels, potentially fewer side effects than opioids.
- DEA determined Supera-CBD is not a controlled substance under the CSA; no scheduling required during development.
- Japanese Patent No. 7293561 B2 issued for Supera-CBD as new molecular entity; company now holds 23 issued patents worldwide.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1321834/000149315223037679/0001493152-23-037679-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1321834/000149315223037679/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-037679

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer